Support: North American Spine Society (NASS) Research Grant Award, Ronald Apfelbaum Research Award from AANS/CNS Section on Disorders of the Spine and Peripheral Nerves Research Grant, Combined Johns Hopkins Medical Institutions and National Institutes of Health (NIH) Neuro-Oncology Research Training Program
Principle Investigator: D.M. Sciubba
Current treatment modalities for metastatic spinal tumors center around focused radiotherapy and surgical excision. As yet, chemotherapy has not been a major modality for the treatment of metastatic spinal tumors due to the advanced stages of the tumors involved, although rare reports of successful systemic chemotherapeutic regimens have appeared in the literature. Although the addition of effective chemotherapeutic regimens to the current scheme for the management of metastatic spinal tumors is largely unexplored, it could be a powerful treatment modality.
We have previously published on local placement of gel-like substances containing chemotherapy agents into the spine tumors of rats. More recently we have also placed molecules know as shRNA (short-inhibitory RNA) into tumors that make such lesions more sensitive to ionizing radiation, so-called radiation sensitizing molecules. Such local treatment with chemotherapy can potentially improve local control of spine tumors leading to improvement in neurological function and potentially survival.
Borrowed from: Bagley CA, et al. Local delivery of OncoGel delays paresis in rat metastatic spinal tumor model. J Neurosurg Spine 7:194–198, 2007